Does Tricare Cover GLP-1 Medications in 2026?

Introduction

Tricare covers GLP-1 medications in 2026, but coverage depends on the specific drug, the FDA indication, and the patient category. For type 2 diabetes, Ozempic®, Mounjaro®, and Trulicity® are covered with prior authorization. For obesity, Wegovy® and Zepbound® are covered when PA criteria are met.

This is a practical coverage guide. It covers what is on the formulary, what PA looks like, how active duty considerations differ from retirees and dependents, and what to do if you get denied. It pulls from current Tricare pharmacy policy and Express Scripts formulary data updated through Q1 2026.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

Which GLP-1 Medications Does Tricare Cover?

Tricare covers Ozempic, Mounjaro, Trulicity, Rybelsus®, and Victoza® for type 2 diabetes. For obesity, Tricare covers Wegovy, Zepbound, and Saxenda® when prior authorization criteria are met.

Quick Answer: Diabetes GLP-1s (Ozempic, Mounjaro, Trulicity) are covered with PA

Coverage runs through Express Scripts as the pharmacy benefit manager for most Tricare plans (Tricare Select, Tricare Prime, Tricare for Life, Tricare Reserve Select). Active duty members at military treatment facilities have parallel access through MTF pharmacies.

Compounded semaglutide and tirzepatide are not covered. Tricare is consistent across all plan types in excluding compounded medications from the pharmacy benefit.

What Are the PA Requirements for Wegovy and Zepbound?

Tricare prior authorization for Wegovy and Zepbound for obesity requires BMI 30+, or BMI 27+ with at least one comorbidity (type 2 diabetes, hypertension, hyperlipidemia, OSA, or established cardiovascular disease), plus documented six-month lifestyle modification attempt.

For Wegovy specifically, the cardiovascular indication added in March 2024 (based on SELECT trial, Lincoff et al. 2023 NEJM) provides an alternate PA path. Patients with established CV disease and BMI 27+ may qualify under the CV indication regardless of obesity-specific criteria.

For Zepbound, the OSA indication added in December 2024 (based on SURMOUNT-OSA) provides an alternate PA path. Patients with moderate-to-severe OSA (AHI 15+) and BMI 30+ may qualify under the OSA indication.

How Does the PA Process Work?

Your prescriber submits a PA request through Express Scripts with diagnosis codes, BMI, comorbidity documentation, prior treatment trials, and supporting clinical notes. Express Scripts reviews and responds within 72 hours for standard requests.

Required documentation typically includes the prescription, two years of relevant medical records, prior weight-loss attempt history, lab values (lipid panel, A1c, CMP), and any comorbidity workup (sleep study for OSA indication, CV imaging for SELECT indication).

If approved, the PA is typically valid for 6-12 months. Renewal requires documented clinical response: weight loss for obesity indications, AHI improvement for OSA, or stable CV status for the SELECT indication.

What Clinical Evidence Does Tricare Reference?

Tricare pharmacy policy references the FDA registration trials for each GLP-1. STEP 1 (Wilding et al. 2021 NEJM) showed 14.9% mean weight loss at 68 weeks for Wegovy. SURMOUNT-1 (Jastreboff et al. 2022 NEJM) showed 20.9% mean weight loss at 72 weeks for Zepbound.

For the Wegovy cardiovascular indication, Tricare references SELECT (Lincoff et al. 2023 NEJM), which showed 20% reduction in major adverse cardiovascular events over 39-month mean follow-up in patients with established CVD and BMI 27+.

For the Zepbound OSA indication, Tricare references SURMOUNT-OSA, which showed AHI reduction of 27-30 events per hour over 52 weeks in patients with moderate-to-severe OSA and obesity.

What Is Different for Active Duty Members?

Active duty members face additional readiness considerations that retirees and dependents do not. Weight standards compliance, physical readiness testing, and deployment status can all interact with GLP-1 therapy.

PA approval for active duty members may route through the military treatment facility pharmacy rather than through Express Scripts. Service-specific medical readiness regulations apply, and the prescriber needs to coordinate with the MTF on dispensing.

Active duty members are usually required to fill at MTF pharmacies when the drug is stocked. Cost at MTF is zero for active duty. Off-base civilian pharmacy fills require additional approval and follow standard Tricare copay rules.

What Is the Copay Structure?

Tricare Prime active duty members pay nothing at MTF pharmacies. Tricare Prime retirees and dependents pay $0-13 for generic and $36-44 for non-formulary brand drugs at network pharmacies, depending on plan year.

Tricare Select copays for non-formulary brand drugs run $40-60 per 30-day supply. Tricare for Life beneficiaries follow Medicare-equivalent structure with low copays for covered medications. Tricare Reserve Select follows similar copay tiers to Tricare Select.

Mail-order pharmacy through Express Scripts offers 90-day supplies at reduced cost. For chronic GLP-1 therapy, mail-order is usually the most cost-effective option.

Key Takeaway: PA requires BMI 30+, or BMI 27+ with comorbidity, plus six-month lifestyle attempt

What If My PA Gets Denied?

Tricare has a two-level appeal process. Level 1 reconsideration with Express Scripts must be filed within 90 days of the denial. Level 2 formal appeal to the Defense Health Agency follows if Level 1 denies, with another 90-day window.

Peer-to-peer review between your prescriber and an Express Scripts clinical reviewer is available and often resolves cases that fail on paper. It is requested through the Express Scripts portal or by phone and usually concluded within a week.

If both appeal levels deny, your real options are switching to a covered alternative (phentermine, orlistat, naltrexone-bupropion) or pursuing cash-pay through a compounding provider.

Can I Get a Compounded GLP-1 Through Tricare?

No. Tricare does not cover compounded medications under any plan type. Compounded semaglutide and tirzepatide are cash-pay only.

If you want compounded GLP-1 therapy, TrimRx offers a free assessment quiz that screens for eligibility and connects qualifying patients with licensed providers for a personalized treatment plan. Costs run substantially below brand retail.

Compounded options are 503A and 503B pharmacy-sourced. The FDA’s 2025 guidance limited some compounding scenarios as Wegovy and Zepbound moved off the shortage list. Compounders working under traditional 503A authority (patient-specific clinical need) continue to operate legally in 2026.

What Clinical Trial Data Does Tricare Policy Reference?

Tricare pharmacy policy references the FDA registration trials for each covered GLP-1. STEP 1 (Wilding et al. 2021 NEJM) showed Wegovy 14.9% mean weight loss at 68 weeks. SURMOUNT-1 (Jastreboff et al. 2022 NEJM) showed Zepbound 20.9% mean weight loss at 72 weeks.

For the SELECT cardiovascular indication, Tricare references Lincoff et al. 2023 NEJM showing 20% MACE reduction over 39-month mean follow-up. For the SURMOUNT-OSA indication, Tricare references the 2024 trial publication showing AHI reduction of 27-30 events per hour.

The SUSTAIN program established Ozempic’s diabetes efficacy. SUSTAIN 6 (Marso et al. 2016 NEJM) demonstrated cardiovascular risk reduction in T2D patients with established CVD. SURPASS-2 (Frias et al. 2021 NEJM) compared Mounjaro to injectable semaglutide, showing greater A1c reduction with Mounjaro 15 mg.

What Happens at PA Renewal?

Tricare PA approvals for GLP-1s typically run 6-12 months. Renewal requires documented clinical response. For diabetes indications, A1c improvement is the standard. For obesity indications, weight loss of at least 5% from baseline is typical.

The renewal submission should include current weight (for obesity), current A1c (for diabetes), AHI improvement and CPAP compliance status (for OSA), or stable CV status (for the SELECT indication). The prescriber typically updates the original PA submission with current values.

If renewal is denied, the same two-level appeal structure applies as for initial denials. Continuing therapy during the appeal period is possible through cash-pay or transition to manufacturer assistance programs.

Bottom line: Compounded GLP-1s are not covered by Tricare

FAQ

Does Tricare Cover Ozempic for Weight Loss?

No. Ozempic is FDA-approved only for type 2 diabetes. Tricare will cover Ozempic for diabetes but not for off-label weight-loss use.

Does Tricare Cover Wegovy for Cardiovascular Risk Reduction?

Yes, when PA criteria are met. The cardiovascular indication requires documented established CVD and BMI 27+.

Does Tricare Cover Zepbound for OSA?

Yes, when PA criteria are met. The OSA indication requires a sleep study showing AHI of 15+ and BMI of 30+.

What Is the Difference Between Tricare Prime and Tricare SELECT for GLP-1 Coverage?

The coverage rules and PA criteria are the same. Copay structure differs. Prime has lower copays at network providers. Select has higher copays but more provider flexibility.

Can Active Duty Members Use Wegovy or Zepbound?

Yes, when PA is approved. Service-specific readiness considerations apply, and active duty usually need MTF coordination.

Does Tricare for Life Cover GLP-1s?

Yes, following the same PA criteria as other Tricare plans. Tricare for Life pays after Medicare, so Medicare Part D rules also apply for retirees over 65.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.